Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib vs Docetaxel in 2nd Line NSCLC with KRAS/NRAS/BRAF/MEK1 Mutations
NCT01362296Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Primary completion
- Sep 2012
- Countries
- 8
01
Overview
A Phase 2 trial of trametinib in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Sep 2011; status: completed.
02
Drugs
trametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01362296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362296.